GIANT CELL ARTERITIS (GCA)
Clinical trials for GIANT CELL ARTERITIS (GCA) explained in plain language.
Never miss a new study
Get alerted when new GIANT CELL ARTERITIS (GCA) trials appear
Sign up with your email to follow new studies for GIANT CELL ARTERITIS (GCA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to tame giant cell arteritis with fewer steroids
Disease control CompletedThis phase 3 trial tested secukinumab, a biologic drug, in 354 people with giant cell arteritis (GCA), a condition causing inflamed arteries. Participants received either secukinumab or a placebo, along with a steroid taper. The goal was to see if secukinumab could help more peop…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
New pill may help patients with rare artery disease ditch steroids faster
Disease control CompletedThis study tested a drug called upadacitinib for people with giant cell arteritis, a condition that causes inflamed arteries. The goal was to see if adding this drug to a shorter course of steroids could help patients achieve remission faster and with fewer side effects. 429 adul…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC
-
Which drug better protects GCA Patients' hearts? large study investigates
Knowledge-focused CompletedThis study looked at over 1,600 people with giant cell arteritis (GCA), a condition that causes blood vessel inflammation and raises heart risks. Researchers compared two treatments—tocilizumab and methotrexate—to see which one better prevented heart attacks, strokes, or death. U…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Sponsor: Groupe français d'étude des Maladies Inflammatoires de loeil • Aim: Knowledge-focused
Last updated Jun 09, 2026 12:06 UTC